MBX Biosciences, Inc. Common Stock
MBX
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.9B
$61.72
▲ +0.49%
P/E
-25.72
Mkt Cap
$2.9B
52-Wk Range
$9.63–$72.64
52-Week Range
$9.63 - $72.64
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 466.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary peptide prodrug platform enabling long-acting formulations with improved patient compliance
- First-mover advantage in dual GLP-1/GIP co-agonist space for obesity treatment
- Focused pipeline targeting underserved endocrine and metabolic disorders with limited treatment options
- Clinical-stage validation of novel mechanisms addressing significant unmet medical needs
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Stable outlook
Expansion of obesity treatment market driven by GLP-1 receptor agonist adoption and demand for alternatives
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+112.8% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying MBX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.78 vs -$0.63 consensus (-23.3% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-23.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · Aug 7, 2026
vs Industry
How MBX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related